Supplementary Tables S1-S19 from Detection of Human Brain Cancers using Genomic and Immune Cell Characterization of Cerebrospinal Fluid through CSF-BAM

Supplementary Table S1: Cohorts for CSF-BAM components. Supplementary Table S2A: SafeBSeqS primer sequences. Supplementary Table S2B: SafeTseqS primer sequences. Supplementary Table S2C: Aneuploidy analysis primer sequences. Supplementary Table S2D: Mutation analysis primer sequences. Genomic coordinates refer to hg19. Supplementary Table S3: Summary of SafeBSeqS analysis in WBC control samples. Supplementary Table S4: Summary of CSF-BAM SafeBSeqS analysis in CSF. Supplementary Table S5: Summary of SafeTSeqS analysis in WBC control samples. Supplementary Table S6: Summary of CSF-BAM SafeTSeqS analysis in CSF. Supplementary Table S7: SafeBSeqS and SafeTSeqS analysis for CSF validation set 2. Supplementary Table S8: Summary of aneuploidy analysis in control samples. Supplementary Table S9: Summary of CSF-BAM aneuploidy analysis in CSF samples. Supplementary Table S10: Reproducibility of aneuploidy analysis. Supplementary Table S11: Comparison of aneuploidy analysis with CSF-BAM and Real-CSF. Supplementary Table S12: CSF-BAM mutation training set in non-cancer CSF samples. Supplementary Table S13: CSF-BAM mutation analysis in CSF samples. Supplementary Table S14: Demographic characteristics by sample. Supplementary Table S15: Diagnostic categories by sample. Supplementary Table S16: CSF-BAM results summary. Supplementary Table S17: CSF-BAM detection based on CSF reservoir abutment by sample. All samples with available clinical data are included. P-values were calculated by Fisher’s exact test. Supplementary Table S18A: TCR Clusters obtained via CSF-BAM. Supplementary Table S18B: TCR specificity annotation. Supplementary Table S19: CSF samples from patients with multiple sclerosis analyzed with SafeTSeqS and SafeBSeqS.